|
|
|
| Progress in Real-World Studies on Neovascular Age-Related Macular Degeneration Based on Electronic Information Platforms |
| Mengxi Shen1, Fenghua Wang1, 2, Xiaodong Sun1, 2, 3 |
1 Department of Ophthalmology, Shanghai General Hospital, School of Medicine, Shanghai Jiao TongUniversity, Shanghai 200080, China
2 Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai 200080, China
3 Shanghai Key Laboratory of Fundus Diseases, Shanghai 200080, China |
|
|
|
|
Abstract Age-related macular degeneration (AMD) is one of the major causes of blindness around the world.Anti-vascular endothelial growth factor (anti-VEGF) therapy has become the first-line therapy for treating neovascular AMD (nAMD). Considering the burden of the high cost of anti-VEGF medicine, long-term and often lifelong repeated injections required of patients, it is important to understand the patterns of anti-VEGF therapy for nAMD patients in real-world settings, which will optimize the delivery of healthcare for nAMD patients, improve clinical pathways and may even help with decision-making in healthcare policy. Recently, data analysis studies on nAMD, based on electronic information platforms, have unveiled the epidemiology of nAMD in different countries and regions, the anti-VEGF therapy patterns in the real
world and the medical expenditure related to nAMD. This article reviews research progress in real-world studies on nAMD based on electronic information platforms.
|
|
Received: 21 November 2018
|
| Fund: Science and Technology Commission of Shanghai Municipality (16411952900); National Natural Science Foundation of China (81470640); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20152229) |
|
Corresponding Authors:
Xiaodong Sun, Department of Ophthalmology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai 200080, China; Shanghai Key Laboratory of Fundus Diseases, Shanghai 200080, China (Email: xdsun@sjtu.edu.cn)
|
|
|
|
| [1] |
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob Health, 2014, 2(2): e106-16. DOI: 10.1016/S2214-109X(13)70145-1.
|
| [2] |
Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration. Lancet, 2012, 379(9827): 1728-1738. DOI:10.1016/S0140-6736(12)60282-7.
|
| [3] |
Cheung CM, Wong TY. Treatment of age-related macularde generation. Lancet, 2013, 382(9900): 1230-1232. DOI:10.1016/S0140-6736(13)61580-9.
|
| [4] |
Brown DM, Michels M, Kaiser PK, et al, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year
|
|
results of the ANCHOR study. Ophthalmology, 2009, 116(1):57-65. DOI: 10.1016/j.ophtha.2008.10.018.
|
| [5] |
Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 2006, 355(14): 1419-1431. DOI:
|
| 10 |
1056/NEJMoa054481.
|
| [6] |
Singer MA, Awh CC, Sadda S, et al. HORIZON: An open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology,2012, 119(6): 1175-1183. DOI: 10.1016/j.ophtha.2011.12.016.
|
| [7] |
孙鑫, 谭婧, 唐立, 等. 重新认识真实世界研究.中国循证医学杂志, 2017, 17(2): 126-130.
|
| [8] |
梁远波, 吴越, 郑景伟.“ 真实世界”研究的产生背景、概念、方法及其在眼科的应用. 中华眼视光学与视觉科学杂志,2013, 15(12): 756-759. DOI:10.3760/cma.j.issn.1674-845X.2013.12.014.
|
| [9] |
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence-what is it and what can it tell us? N Engl J Med, 2016,375(23): 2293-2297. DOI: 10.1056/NEJMsb1609216.
|
| [10] |
郝良军. 医院信息系统在医院管理中的应用价值研究. 中国药物与临床, 2018, 18(7): 1244-1245. DOI:10.11655/zgywylc2018.07.086.
|
| [11] |
Kimura S, Sato T, Ikeda S, et al. Development of a database of health insurance claims: Standardization of disease classifications and anonymous record linkage. J Epidemiol, 2010, 20(5): 413-419.
|
| [12] |
Altman D, Frist WH. Medicare and medicaid at 50 years:Perspectives of beneficiaries, health care professionals and institutions, and policy makers. JAMA, 2015, 314(4): 384-395.
|
|
DOI: 10.1001/jama.2015.7811.
|
| [13] |
Adler-Milstein J, Holmgren AJ, Kralovec P, et al. Electronic health record adoption in US hospitals: The emergence of a digital "advanced use" divide. J Am Med Inform Assoc, 2017,
|
| 24 |
(6): 1142-1148. DOI: 10.1093/jamia/ocx080.
|
| [14] |
Rao P, Lum F, Wood K, et al. Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry. Ophthalmology, 2018,125(4): 522-528. DOI: 10.1016/j.ophtha.2017.10.010.
|
| [15] |
Ng WY, Cheung CM, Mathur R, et al. Trends in age-related macular degeneration management in Singapore. Optom Vis Sci,2014, 91(8): 872-877. DOI:10.1097/OPX.0000000000000283.
|
| [16] |
Lad EM, Hammill BG, Qualls LG, et al. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. Am J Ophthalmol, 2014, 158(3):537-543. DOI: 10.1016/j.ajo.2014.05.014.
|
| [17] |
Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.N Engl J Med, 2011, 364(20): 1897-1908. DOI: 10.1056/
|
|
NEJMoa1102673.
|
| [18] |
Holz FG, Korobelnik JF, Lanzetta P, et al. The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: Outcomes of a drug and
|
|
disease model. Invest Ophthalmol Vis Sci, 2010, 51(1): 405-412. DOI: 10.1167/iovs.09-3813.
|
| [19] |
Curtis LH, Hammill BG, Qualls LG, et al. Treatment patterns for neovascular age-related macular degeneration: Analysis of 284 380 medicare beneficiaries. Am J Ophthalmol, 2012, 153(6):1116-1124. DOI: 10.1016/j.ajo.2011.11.032.
|
| [20] |
Obeid A, Gao X, Ali FS, et al. Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti-vascular endothelial growth factor injections. JAMA Ophthalmol, 2018, 136(11): 1251-1259. DOI: 10.1001/jamaophthalmol.2018.3578.
|
| [21] |
Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: Multicenter study of 92 976
|
|
ranibizumab injections: Report 1: Visual acuity. Ophthalmology,2014, 121(5): 1092-1101. DOI: 10.1016/j.ophtha.2013.11.031.
|
| [22] |
Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists
|
|
(EURETINA). Br J Ophthalmol, 2014, 98(9): 1144-1167. DOI:10.1136/bjophthalmol-2014-305702.
|
| [23] |
Day S, Acquah K, Lee PP, et al. Medicare costs for neovascular age-related macular degeneration, 1994-2007. Am J Ophthalmol, 2011, 152(6): 1014-1020. DOI: 10.1016/j.ajo.2011. 05.008.
|
| [24] |
Schmier JK, Covert DW, Lau EC. Patterns and costs associated with progression of age-related macular degeneration. Am J Ophthalmol, 2012, 154(4): 675-681. DOI: 10.1016/j.ajo.2012.04.017.
|
| [25] |
Brown MM, Brown GC, Lieske HB, et al. Societal costs associated with neovascular age-related macular degeneration in the United States. Retina, 2016, 36(2): 285-298. DOI: 10.1097/ IAE.0000000000000717.
|
| [26] |
Windsor MA, Sun SJJ, Frick KD, et al. Estimating public and patient savings from basic research―A study of optical coherence tomography in managing antiangiogenic therapy. Am
|
|
J Ophthalmol, 2018, 185: 115-122. DOI: 10.1016/j.ajo.2017.09.027.
|
|
|
|
